Phacotrabeculectomy augmented with mitomycin-C (MMC) vs phacotrabeculectomy augmented with Ologen implant: efficacy and safety

Session Details

Session Title: Glaucoma II

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 10:00

Venue: Room 17

First Author: : B.Kudsieh SPAIN

Co Author(s): :    J. Rosandic   T. Perez de los Cobos   M. Canut              

Abstract Details

Purpose:

To compare the results of Phacotrabeculectomy augmented with mitomycin-C (MMC) Versus Ologen implant regarding intraocular pressure (IOP) control, bleb and incidence of complications.

Setting:

laucoma department , Instituto Universitario Barraquer, Autónomas University of Barcelona, Barcelona, Spain

Methods:

Ten consecutive Caucasian patients underwent phacotrabeculectomy augmented with MMC in one eye and phacotrabeculectomy augmented with Ologen implant in the other eye. Main Outcome Measures: primary outcome was IOP at 1, 3, 6, 12 months, bleb grading with Moorfields grading scale. Additional postoperative treatments, such as bleb needling, and complications were secondary outcomes.

Results:

The intraocular pressure was 16.5+/-7 in the Ologen group and 14.4+/-3 in the mitomycin C group at 1 month after surgery. The intraocular pressure was 15.2+/-3 in the Ologen group and 16.0+/-5 in the mitomycin C group at 1 year after surgery. During the first 6 months, the group of Ologen had greater central and maximum area while at 1 year no differences were observed between two groups. Needling with 5-fluorouracil was just in the Ologen group (20%) No complications were observed in both groups.

Conclusions:

Phacotrabeculectomy showed similar results with the use of Ologen implant or MMC, eyes in the Ologen group had higher IOP during the first month and required more frequent bleb needling procedures. Financial Disclosure: the authors declare no financial interest in any product of the study.

Financial Interest:

NONE